Our research study is evaluating the long-term efficacy and safety of a new investigational GLP-1 treatment option for adults living with MASH and liver fibrosis.
Those who qualify and choose to participate will be compensated for their study-related time and travel.
This study is looking at whether the study drug, Survodutide, can help improve liver conditions like MASH and fibrosis after a year of treatment and lower the chances of severe liver disease after about seven years in adults with moderate to advanced liver damage.
If you qualify and choose to participate, there is a 67% chance you will receive the study drug and a 33% chance you will receive a placebo. A placebo is an inactive material that looks like Survodutide but does not contain any active study drug.
You will be on this study for about 4.5 years which will include a screening period, a dose escalation period, a maintenance period, and a follow-up period. The study will require in-clinic visits and remote (over the phone) visits, the frequency of which will depend on your fibrosis level. If you qualify and choose to participate, you will be compensated for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.
For more information on the study, please click here to visit the official study website.
Survodutide is an investigational GLP-1 that targets two specific receptors in the body to help manage metabolism. It's currently being tested in advanced clinical trials, including studies focused on people with liver issues and those who are overweight or obese.
For more information on Survodutide, please click here to visit the Boehringer Ingelheim page.
Those who qualify and choose to participate could receive:
Access to our top-tier team of board-certified physicians at no cost
Compensation for study-related time and travel
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be approved by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.